Breast scintigraphy with technetium-99m NC100692 is safe and effective and could be used to monitor cancer treatment response, according to a study published in the September issue of the Journal of Nuclear Medicine.

Researchers at the Karolinska Institute of Stockholm and the Norwegian Radiumhospital in Oslo tested Tc-99m NC100692 in a study of 16 patients with suspicious mammograms and four patients with benign breast lesions 6 mm or larger. Imaging with the new agent detected 19 of 22 malignant lesions.

No serious adverse events were encountered with the new agent, though mild side effects occurred in five patients. Tc-99m sestamibi has been used in the past to support mammography, but its sensitivity never went beyond 50% for lesions smaller than 12 mm. Tc-99m NC100692 showed 100% sensitivity for lesions 10 mm or larger.

 CT modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of CT across the healthcare continuum, from various cancer screenings, such as lung and colon, to cardiothoracic imaging, to appendicitis, and more.

Breast scintigraphy with technetium-99m NC100692 is safe and effective and could be used to monitor cancer treatment response, according to a study published in the September issue of the Journal of Nuclear Medicine

New agent proves its value in breast scintigraphy scans